Navigation Links
AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008

Patients filled 2.7 million prescriptions through AZ&Me(TM) Prescription Savings Programs

WILMINGTON, Del., Feb. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it provided $612.6 million in savings to 440,541 patients in the United States last year through its AZ&Me(TM) Prescription Savings programs.

Patients filled 2.7 million prescriptions through the programs in 2008.

"AstraZeneca is committed to helping patients who are facing health and financial challenges," said Rich Fante, President of AstraZeneca US. "Our prescription savings programs provide support for patients who might otherwise go without the medicines they need."

AstraZeneca provides free or low-cost medicines to patients through its AZ&Me(TM) Prescription Savings programs in three ways:

  • Individuals: AstraZeneca provides free medicines to qualifying individuals without prescription drug coverage who make up to $30,000 per year and families of four with $60,000 annual household income.

  • Part D beneficiaries: AstraZeneca provides low-cost medicines for qualifying Medicare Part D patients who make up to $30,000 per year or couples who make up to $40,000 per year.

  • Healthcare facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program connects patients to the medicines they need at the same time and place they receive their treatment.

AstraZeneca has offered prescription savings programs side by side with its medicines for three decades and offers one of the industry's most generous programs.

In 2009, AstraZeneca will continue to reach patients who need help through a variety of channels, including community health centers, our product advertisements, and health care professionals and advocates, who are the leading source of information about our programs, according to an AstraZeneca survey. The company also participates in the Partnership for Prescription Assistance, a multi-company program.

Patients can learn more about the AZ&Me Prescription Savings program at or by calling 1-800-AZandMe.

A podcast related to this news release can be found here.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
2. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
3. AstraZenecas Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
4. AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva
5. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
6. AstraZenecas Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008
7. AstraZeneca Recognized as One of Working Mother Magazines 100 Best Companies
8. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
9. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
10. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
11. A Drug That Carries a Lower Risk of Weight Gain Than AstraZenecas Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology: